ERIS Lifesciences Ltd
NSE: ERIS BSE: 540596
₹1150
(0.03%)
Sat, 17 Oct 2026, 06:18 pm
Market Cap (in Cr)15955.63
PE Ratio24.49
Dividend0.63
Health Technology
Pharmaceuticals: Major
24.5KERIS Lifesciences Financials
| Particulars | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 2.74B | 3.93B | 5.09B | 5.46B | 5.85B | 7.21B | 8.48B | 9.82B | 10.74B | 12.12B | 13.47B | 16.85B | 20.09B | 28.94B |
| Gross profit | 1.76B | 2.43B | 3.10B | 3.00B | 3.32B | 4.51B | 5.21B | 5.90B | 6.28B | 6.91B | 7.61B | 8.54B | 10.13B | 13.01B |
| Operating expenses (excl. COGS) | -1.20B | -1.60B | -2.16B | -1.93B | -1.78B | -2.04B | -2.24B | -2.79B | -3.01B | -2.95B | -3.30B | -4.25B | -4.94B | -5.88B |
| Selling/general/admin expenses, total | -1.20B | -1.59B | -2.14B | -1.85B | -1.85B | -2.01B | -2.21B | -2.73B | -2.94B | -2.89B | -3.22B | -4.16B | -4.84B | -5.76B |
| Research & development | — | — | — | — | — | — | -7.74M | -41.12M | -41.96M | -50.92M | -327.38M | -61.00M | -57.20M | -24.40M |
| Selling/general/admin expenses, other | -1.20B | -1.59B | -2.14B | -1.85B | -1.85B | -2.01B | -2.20B | -2.69B | -2.90B | -2.84B | -2.89B | -4.10B | -4.79B | -5.74B |
| Other operating expenses, total | -7.33M | -9.72M | -20.09M | -88.20M | 72.93M | -33.00M | -30.55M | -63.13M | -65.34M | -57.38M | -80.87M | -92.19M | -98.20M | -116.70M |
| Operating income | 553.61M | 831.44M | 942.83M | 1.06B | 1.54B | 2.47B | 2.97B | 3.11B | 3.27B | 3.96B | 4.31B | 4.29B | 5.18B | 7.14B |
| Non-operating income, total | 1.24M | -50.00K | 40.42M | 33.61M | 2.38M | 237.02M | 148.78M | 63.79M | 38.55M | -16.73M | 108.43M | -248.41M | -869.20M | -2.25B |
| Interest expense, net of interest capitalized | -11.85M | -7.67M | -2.75M | -220.00K | -2.77M | -2.53M | -100.87M | -230.60M | -22.97M | -19.75M | -42.19M | -263.45M | -848.00M | -2.31B |
| Interest capitalized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 13.09M | 8.68M | 43.17M | 33.83M | 32.56M | 48.07M | 45.69M | 32.44M | 61.52M | 3.02M | 131.94M | 15.04M | -21.20M | 63.60M |
| Non-operating interest income | 9.01M | 2.76M | 1.70M | 840.00K | 4.18M | 8.56M | 9.96M | 10.96M | 16.06M | 22.85M | 60.98M | 22.99M | 70.10M | 50.60M |
| Miscellaneous non-operating expense | 4.08M | 5.92M | 41.47M | 32.99M | 28.38M | 39.50M | 35.73M | 2.42M | 30.43M | -29.74M | 66.13M | -12.73M | -95.80M | 6.70M |
| Unusual income/expense | — | -1.06M | — | — | -27.41M | 191.48M | 203.96M | 261.95M | 0 | 0 | 18.68M | 0 | 0 | 200.00K |
| Pretax income | 554.85M | 831.39M | 983.25M | 1.09B | 1.54B | 2.70B | 3.12B | 3.17B | 3.31B | 3.94B | 4.42B | 4.05B | 4.31B | 4.89B |
| Taxes | -184.22M | -246.99M | -274.13M | -201.56M | -195.87M | -237.80M | -172.51M | -262.11M | -348.43M | -393.62M | -364.09M | -304.83M | -342.20M | -1.14B |
| Non-controlling/minority interest | -1.20M | -2.42M | -1.18M | -250.00K | -12.88M | 1.78M | -8.73M | -3.51M | -100.00K | 0 | 3.24M | 79.98M | -50.70M | -228.30M |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 369.43M | 581.98M | 707.94M | 892.34M | 1.34B | 2.47B | 2.94B | 2.91B | 2.96B | 3.55B | 4.06B | 3.82B | 3.92B | 3.52B |
| Net income | 369.43M | 581.98M | 707.94M | 892.34M | 1.34B | 2.47B | 2.94B | 2.91B | 2.96B | 3.55B | 4.06B | 3.82B | 3.92B | 3.52B |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | 369.43M | 581.98M | 707.94M | 892.34M | 1.34B | 2.47B | 2.94B | 2.91B | 2.96B | 3.55B | 4.06B | 3.82B | 3.92B | 3.52B |
| Basic earnings per share (Basic EPS) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | 586.05M | 866.61M | 990.78M | 1.22B | 1.75B | 2.69B | 3.23B | 3.47B | 3.78B | 4.39B | 4.96B | 5.47B | 7.01B | 10.29B |
| EBIT | 553.61M | 831.44M | 942.83M | 1.06B | 1.54B | 2.47B | 2.97B | 3.11B | 3.27B | 3.96B | 4.31B | 4.29B | 5.18B | 7.14B |
| Total operating expenses | -2.19B | -3.10B | -4.15B | -4.40B | -4.31B | -4.74B | -5.51B | -6.71B | -7.47B | -8.16B | -9.16B | -12.56B | -14.91B | -21.80B |
| Prepaid expenses | 3.96M | 8.03M | 8.97M | 8.38M | 9.81M | 11.16M | 37.01M | 69.83M | 59.98M | 79.90M | 214.39M | 172.83M | 256.20M | 200.40M |
| Deferred income, current | 2.23M | 2.86M | 3.62M | 5.92M | 3.42M | 3.50M | 20.97M | 26.16M | 24.84M | 28.93M | 38.71M | 33.35M | 209.20M | 187.70M |
| Capital and operating lease obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61.44M | 44.47M | 353.94M | 389.74M | 442.10M | 442.10M |
| Operating lease liabilities | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Deferred tax liabilities | 1.81M | — | 3.45M | — | — | 346.54M | 522.70M | 516.95M | 506.15M | 495.38M | 460.94M | 2.58B | 5.34B | 5.18B |
| Deferred income, non-current | 0 | 0 | 0 | 0 | 0 | 0 | — | 55.71M | 31.07M | — | — | — | — | — |
| Minority interest | 50.08M | 47.48M | 43.55M | 39.24M | 32.01M | 237.93M | 246.65M | 183.11M | 0 | 20.00K | -1.08M | 246.89M | 6.36B | 4.17B |
| Change in accrued expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Common dividends paid | -58.32M | 0 | 0 | 0 | -830.78M | -169.12M | 0 | 0 | -469.79M | -746.79M | -816.23M | -999.11M | 0 | -1.00B |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
